UnitedHealth Group (NYSE:UNH) traded up 3.2% midday Friday, reaching $293.33, despite missing revenue estimates and facing mixed analyst revisions. While Optum’s expansion and some earnings forecast upgrades provide positive sentiment, concerns remain regarding medical-cost inflation, flat Medicare Advantage pricing, and regulatory risks. Analysts currently rate UNH as a “Moderate Buy” with a consensus price target of $372.13.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
UnitedHealth Group (NYSE:UNH) Trading 3.2% Higher - Still a Buy?
UnitedHealth Group (NYSE:UNH) traded up 3.2% midday Friday, reaching $293.33, despite missing revenue estimates and facing mixed analyst revisions. While Optum’s expansion and some earnings forecast upgrades provide positive sentiment, concerns remain regarding medical-cost inflation, flat Medicare Advantage pricing, and regulatory risks. Analysts currently rate UNH as a “Moderate Buy” with a consensus price target of $372.13.